Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer
Preclinical data published for colon cancer product, NX 473
December 23rd, 2004
NeoRx Corporation (NASDAQ:NERX) announced a publication of preclinical data supporting the use of NX 473, the company's next generation platinum product candidate, in colorectal cancer (CRC). The research involved the evaluation of NX 473 given alone and in combination with chemotherapeutics used to treat colorectal cancer. The peer-reviewed publication "Antiproliferative Effects of ZD0473 (AMD473) in Combination with 5-Fluorouracil or SN38 in Human Colorectal Cell Lines" appears in the Investigational New Drugs. "This publication provides compelling data that demonstrate NX 473 is active in colorectal cell lines sensitive or resistant to...
Source: Women's Health Weekly (2004-12-23)
|
